West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With almost 10,000 team members across 50 sites worldwide, West helps support its customers by delivering over 40 billion components and devices each year.
Company profile
Ticker
WST
Exchange
Website
CEO
Eric Green
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
WEST CO INC
SEC CIK
Corporate docs
Subsidiaries
West Pharmaceutical • Tech Group Europe Limited • Tech Group • TGPR Holdings Limited • WD SG Pte. Ltd. • West Analytical Services, LLC • West Contract Manufacturing, LLC • West Pharma. Services IL, Ltd. • West Pharmaceutical Products Ireland, Ltd. • West Pharmaceutical Services Australia ...
IRS number
231210010
WST stock data
News
Here's How Much $1000 Invested In West Pharmaceutical Servs 10 Years Ago Would Be Worth Today
5 Aug 22
West Pharmaceutical Servs's Return On Capital Employed Insights
3 Aug 22
How Is The Market Feeling About West Pharmaceutical Servs?
2 Aug 22
West Pharmaceutical Services: Q2 Earnings Insights
28 Jul 22
West Pharmaceutical Servs Q2 EPS $2.47 Beats $2.21 Estimate, Sales $771.30M Beat $755.57M Estimate
28 Jul 22
Press releases
West Announces Second-Quarter 2022 Results
28 Jul 22
West Elects New Director to the Board
27 Jul 22
West to Host Second-Quarter 2022 Conference Call
14 Jul 22
West Pharmaceutical Services Releases 2021 Corporate Responsibility Report
12 Jul 22
West Introduces Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention
13 Jun 22
Calendar
28 Jul 22
9 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Aug 22 | Birkett Bernard | Common Stock | Sell | Dispose S | No | No | 343.3845 | 1,100 | 377.72K | 795 |
| 2 Aug 22 | Birkett Bernard | Common Stock | Sell | Dispose S | No | No | 342.5877 | 2,007 | 687.57K | 1,895 |
| 2 Aug 22 | Birkett Bernard | Common Stock | Sell | Dispose S | No | No | 341.9691 | 1,708 | 584.08K | 3,902 |
| 2 Aug 22 | Birkett Bernard | Common Stock | Sell | Dispose S | No | No | 340.4952 | 9,359 | 3.19M | 5,610 |
| 1 Aug 22 | Stephen H Lockhart | Common Stock | Grant | Acquire A | No | No | 0 | 454 | 0 | 454 |
| 1 Aug 22 | Silji Abraham | Common Stock | Sell | Dispose S | No | No | 343.9349 | 5,374 | 1.85M | 3,201.3 |
| 30 Jun 22 | Joseph Molly | Phantom Stock Unit Common Stock | Grant | Acquire A | No | No | 302.37 | 74 | 22.38K | 205 |
Institutional ownership, Q1 2022
| 13F holders | Current |
|---|---|
| Total holders | 692 |
| Opened positions | 72 |
| Closed positions | 92 |
| Increased positions | 239 |
| Reduced positions | 270 |
| 13F shares | Current |
|---|---|
| Total value | 27.92B |
| Total shares | 69.87M |
| Total puts | 163.2K |
| Total calls | 186.6K |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 8.72M | $3.58B |
| BLK Blackrock | 8.08M | $3.32B |
| TROW T. Rowe Price | 6.38M | $2.62B |
| STT State Street | 3.39M | $1.39B |
| BEN Franklin Resources | 2.8M | $1.15B |
| APG Asset Management | 2.54M | $937.28M |
| FMR | 2.03M | $834.78M |
| CFS Investment Advisory Services | 1.55M | $4K |
| WCM Investment Management | 1.53M | $626.94M |
| Geode Capital Management | 1.43M | $585.53M |
Financial report summary
?Competition
InsuletManagement Discussion
- We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items for which further information can be found above in the reconciliation from U.S. GAAP to non-U.S. GAAP financial measures.
- Percentages in the following tables and throughout the Results of Operations section may reflect rounding adjustments.
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
broader, connection, country, energy, European, labor, revised, Russia, Seiko, Ukraine
Removed:
admixture, fluid, licensing, recognition
Financial reports
Current reports
8-K
West Announces Second-Quarter 2022 Results
28 Jul 22
8-K
West Elects New Director to the Board
27 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
25 May 22
8-K
West Announces Executive Leadership Appointments
12 May 22
8-K
West Announces First-Quarter 2022 Results and Declares Third-Quarter 2022 Dividend
28 Apr 22
8-K
Entry into a Material Definitive Agreement
1 Apr 22
8-K
West Names President and CEO Eric M. Green as Chair of the Board
28 Feb 22
8-K
West Announces Fourth-Quarter and Full-Year 2021 Results
17 Feb 22
8-K
West Announces Third-Quarter 2021 Results and Declares Fourth-Quarter 2021 Dividend
28 Oct 21
8-K/A
West Elects New Director to the Board
24 Aug 21
Registration and prospectus
S-8
Registration of securities for employees
2 May 16
SC TO-I/A
Issuer tender offer statement (amended)
5 Jun 12
SC TO-I/A
Issuer tender offer statement (amended)
3 Jun 12
SC TO-C
Information about tender offer
7 May 12
SC TO-I
Issuer tender offer statement
7 May 12
S-8
Registration of securities for employees
11 May 11
S-8
Registration of securities for employees
28 Dec 10
S-8
Registration of securities for employees
29 Dec 08
424B7
Prospectus with selling stockholder info
27 Feb 08
S-3ASR
Automatic shelf registration
6 Aug 07
Proxies
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEFA14A
Additional proxy soliciting materials
24 Mar 21
DEFA14A
Additional proxy soliciting materials
17 Apr 20
DEFA14A
Additional proxy soliciting materials
25 Mar 20
PRE 14A
Preliminary proxy
13 Mar 20
DEFA14A
Additional proxy soliciting materials
22 Mar 19
DEF 14A
Definitive proxy
22 Mar 19
Other
SD
Conflict minerals disclosure
25 May 22
SD
Conflict minerals disclosure
28 May 21
SD
Conflict minerals disclosure
28 May 20
SD
Conflict minerals disclosure
30 May 19
CT ORDER
Confidential treatment order
20 Aug 18
SD
Conflict minerals disclosure
25 May 18
SD
Conflict minerals disclosure
25 May 17
CT ORDER
Confidential treatment order
16 Mar 17
CT ORDER
Confidential treatment order
5 Dec 16
CT ORDER
Confidential treatment order
14 Sep 16
Ownership
4
WEST PHARMACEUTICAL SERVICES / Bernard Birkett ownership change
3 Aug 22
4
WEST PHARMACEUTICAL SERVICES / Silji Abraham ownership change
3 Aug 22
3
WEST PHARMACEUTICAL SERVICES / Stephen H Lockhart ownership change
2 Aug 22
4
WEST PHARMACEUTICAL SERVICES / Stephen H Lockhart ownership change
2 Aug 22
4
WEST PHARMACEUTICAL SERVICES / Molly Joseph ownership change
1 Jul 22
11-K
Annual report of employee stock purchases
23 Jun 22
11-K
Annual report of employee stock purchases
23 Jun 22
4
WEST PHARMACEUTICAL SERVICES / Bernard Birkett ownership change
23 Jun 22
4
WEST PHARMACEUTICAL SERVICES / Molly Joseph ownership change
26 May 22
4
WEST PHARMACEUTICAL SERVICES / William F Feehery ownership change
26 May 22
Patents
Utility
Injector premature activation blocking mechanism
2 Aug 22
An injector includes a housing and an activation button assembly movably mounted thereto and translatable from an unactuated position to an actuated position.
Utility
Smooth Film Laminated Elastomer Articles
21 Jul 22
An elastomeric article for sealing a container includes an elastomeric body having an external sidewall surface and an external crown surface and a first fluoropolymer film layer having an internal surface and an external surface.
Utility
Staged telescopic screw assembly having different visual indicators
19 Jul 22
A telescopic screw assembly for an injector includes an inner screw, an outer screw and a middle screw.
Utility
Needle shield for injection needle retraction
19 Jul 22
An injector includes a housing, a needle hub movably mounted within the housing and an injection needle supported by the hub.
Utility
Adaptive Primary Packaging for Therapeutic Solutions
14 Jul 22
Various container assemblies for containing a therapeutic liquid are provided.
Transcripts
2022 Q2
Earnings call transcript
28 Jul 22
2022 Q1
Earnings call transcript
28 Apr 22
2021 Q4
Earnings call transcript
17 Feb 22
2021 Q3
Earnings call transcript
28 Oct 21
2021 Q2
Earnings call transcript
29 Jul 21
2021 Q1
Earnings call transcript
30 Apr 21
2020 Q4
Earnings call transcript
18 Feb 21
2020 Q3
Earnings call transcript
22 Oct 20
2020 Q2
Earnings call transcript
23 Jul 20
2020 Q1
Earnings call transcript
23 Apr 20
Reddit threads
Daily Discussion Thread - July 28th, 2022
28 Jul 22
Daily Discussion Thread - July 27th, 2022
27 Jul 22
Any Mid-Cap Company Recommendations?
26 Jul 22
Daily Discussion Thread - July 26th, 2022
26 Jul 22
Daily Discussion Thread - July 25th, 2022
25 Jul 22
Daily Discussion Thread - July 19th, 2022
19 Jul 22
Daily Discussion Thread - July 18th, 2022
18 Jul 22
Maybe safe-haven stocks aren’t so safe after all?
30 Jun 22
229 S&P500 companies ($21.6t in market cap, 61.8%) report earnings in the next ~30 days
25 Jun 22
50 stocks with at least 20 years of consecutive years of dividend growth within 10% of their 52-Week Low (List in the comments)
26 May 22